Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Change in Cash (2017 - 2025)

Historic Change in Cash for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to -$54.8 million.

  • Protagonist Therapeutics' Change in Cash rose 7557.79% to -$54.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.3 million, marking a year-over-year increase of 8255.03%. This contributed to the annual value of -$89.5 million for FY2024, which is 24672.61% down from last year.
  • According to the latest figures from Q3 2025, Protagonist Therapeutics' Change in Cash is -$54.8 million, which was up 7557.79% from $29.0 million recorded in Q2 2025.
  • Over the past 5 years, Protagonist Therapeutics' Change in Cash peaked at $183.1 million during Q2 2024, and registered a low of -$224.5 million during Q3 2024.
  • Its 5-year average for Change in Cash is -$200947.4, with a median of -$4.9 million in 2023.
  • Its Change in Cash has fluctuated over the past 5 years, first crashed by 452455.2% in 2024, then skyrocketed by 39948.44% in 2025.
  • Protagonist Therapeutics' Change in Cash (Quarter) stood at $3.1 million in 2021, then plummeted by 966.86% to -$27.1 million in 2022, then crashed by 61.79% to -$43.8 million in 2023, then grew by 22.67% to -$33.9 million in 2024, then plummeted by 61.88% to -$54.8 million in 2025.
  • Its last three reported values are -$54.8 million in Q3 2025, $29.0 million for Q2 2025, and $42.4 million during Q1 2025.